Liver transplantation for hepatitis B: what have we learned and what does the future hold?
Fung
J J
JJ
Pittsburgh Transplantation Institute, University of Pittsburgh Medical Center, PA, USA.
Rakela
J
J
Pinna
A
A
Todo
S
S
D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D004279:DNA, Viral / Q000032:analysis; D006511:Hepatitis B Antigens / Q000276:immunology; D006515:Hepatitis B virus / Q000235:genetics / Q000254:growth & development / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000150:complications / Q000517:prevention & control / Q000601:surgery*; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins; D016898:Interferon-alpha / Q000627:therapeutic use; D017093:Liver Failure / Q000209:etiology / Q000601:surgery; D016031:Liver Transplantation; D010215:Papio; D055502:Secondary Prevention; D014183:Transplantation, Heterologous; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D004279:DNA, Viral; D006511:Hepatitis B Antigens; D007136:Immunoglobulins; D016898:Interferon-alpha; C045213:hepatitis B hyperimmune globulin